Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
This review covers the design and development of B cell Toleragens, compounds developed for the treatment of antibody-mediated autoimmune diseases by antigen-specific suppression of autoantibodies. Multivalent forms of B cell epitopes consisting of oligonucleotides, peptides, proteins and polysaccharides are under various stages of development for treating systemic lupus nephritis, antiphospholipid syndrome, and organ rejection associated with xenotransplantation. The design and structure of the multivalent ligands are presented along with relevant biological results. Hapten-polymer conjugates that were used to elucidate the principles of B cell suppression are included. Multivalent ligands for T cell receptors and high affinity IgE receptors, which provide insight into immunoglobulin aggregation and signaling, are also briefly discussed.
No Supplementary Data
No Article Media
Document Type: Review Article
Affiliations: La Jolla Pharmaceutical Company, 6455 Nancy Ridge Dr., San Diego, CA 92121, USA;
Publication date: August 1, 2005
More about this publication?
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites